Bipolar Disorders Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Bipolar Disorders Treatment Market Report is Segmented by Drug Class (Mood Stabilizers, Anticonvulsants, and More), Mechanism of Action (Selective Serotonin Reuptake Inhibitor, and More), Disease Type (Bipolar I Disorder, and More), Geography (North America, Europe, Asia-Pacific, The Middle East and Africa, and South America). The Market Forecasts are Provided in Terms of Value (USD).

Bipolar Disorders Treatment Market Size and Share

Bipolar Disorders Treatment Market (2025 - 2030)
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Bipolar Disorders Treatment Market Analysis by Mordor Intelligence

The bipolar disorders treatment market is valued at USD 5.01 billion in 2025 and is forecast to reach USD 5.82 billion by 2030, advancing at a 2.55% CAGR. Prescriber preference for second-generation antipsychotics (SGAs), broader reimbursement under mental-health parity rules, and accelerating uptake of digital therapeutics collectively sustain growth momentum. The 2025 acquisition of Intra-Cellular Therapies by Johnson & Johnson vaults Caplyta into a leading position for bipolar depression and underscores renewed strategic emphasis on neuroscience portfolios. Long-acting injectables (LAIs) are proving cost-effective by curbing relapse-linked hospitalizations, while AI-driven diagnostic tools shrink the historical treatment-initiation gap. Competitive focus is shifting toward metabolic-sparing combinations and precision digital monitoring, signaling a market pivot from volume to value.

Key Report Takeaways

  • By drug class, second-generation antipsychotics led with 51.45% of bipolar disorders treatment market share in 2024; antidepressants are projected to expand at a 4.23% CAGR to 2030.
  • By mechanism of action, dopamine D₂/D₃ partial agonists held 37.43% of the bipolar disorders treatment market size in 2024, whereas glutamate pathway modulators record the highest forecast CAGR at 4.78% through 2030.
  • By disease type, bipolar I disorder accounted for 62.34% of the bipolar disorders treatment market size in 2024, while bipolar II disorder is set to grow at a 4.34% CAGR to 2030.
  • By distribution channel, hospital pharmacies captured 46.43% revenue share in 2024; online pharmacies show the fastest growth at 5.45% CAGR through 2030.
  • By treatment setting, inpatient care represented 53.45% of revenue in 2024, and digital therapeutics are advancing at a 5.76% CAGR to 2030.
  • By geography, North America dominated with 42.56% share in 2024; Asia-Pacific registers the quickest expansion at 3.56% CAGR to 2030.

Segment Analysis

By Drug Class: Second-Generation Antipsychotics Dominate Despite Antidepressant Surge

Second-generation antipsychotics held 51.45% of bipolar disorders treatment market share in 2024, underscoring their broad efficacy across all mood phases. Quetiapine and lumateperone illustrate dual dopamine-serotonin modulation that stabilizes mania and depression, aligning with 2024 Veterans Affairs treatment algorithms. Lithium prescriptions fell from 31% to 16% of patients due to monitoring burdens, though its neuroprotective value endures. Anticonvulsants such as lamotrigine safeguard cognitive function and remain central to maintenance therapy.

Antidepressants represent the fastest-growing category, expanding at a 4.23% CAGR as Caplyta gains traction for bipolar depression. Regimens increasingly combine antidepressants with mood stabilizers to prevent manic switching, broadening therapeutic flexibility. Pipeline diversity spans glutamate and GABA modulators that seek superior tolerability. Collectively, these trends reinforce sustained revenue generation inside the bipolar disorders treatment market while opening room for differentiated newcomers across the bipolar disorder industry.

Bipolar Disorders Treatment Market: Market Share by Drug Class
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By Mechanism of Action: Dopamine Modulation Leads While Glutamate Innovation Accelerates

Dopamine D₂/D₃ partial agonists accounted for 37.43% of the bipolar disorders treatment market size in 2024, reflecting a balance of efficacy and softer side-effect profiles. Aripiprazole’s stabilizing action without full receptor blockade typifies this class’s appeal and spurs similar candidates in mid-stage trials.

Glutamate-pathway agents show the highest forward CAGR at 4.78% as ketamine’s rapid antidepressant response validates NMDA receptor targeting. Serotonin-norepinephrine reuptake inhibitors preserve utility where cognitive activation is a therapeutic goal, although selective serotonin reuptake inhibitors require mood-stabilizer co-administration. GABA modulators and ion-channel stabilizers, led by lithium and lamotrigine, continue as backbone options. Mechanistic diversification reduces clinical inertia and broadens prescriber choice throughout the bipolar disorders treatment market.

By Disease Type: Bipolar I Dominance Reflects Severity While Bipolar II Recognition Grows

Bipolar I disorder captured 62.34% of revenue in 2024, owing to full-blown manic episodes that necessitate urgent pharmacologic and often inpatient intervention. Clear diagnostic criteria and greater hospitalization rates translate into higher drug utilization intensity. Cyclothymia and mixed-feature specifiers further enrich clinical complexity and expand the addressable pool.

Bipolar II prevalence is rising and is predicted to climb at a 4.34% CAGR to 2030 as clinician education improves and digital symptom-tracking identifies hypomanic periods. Rapid-cycling forms affect up to 20% of patients and favor anticonvulsant over lithium therapy. Broader spectrum recognition enlarges the bipolar disorders treatment market while underscoring the need for nuanced treatment algorithms across the wider bipolar disorder industry.

By Distribution Channel: Hospital Pharmacy Strength Versus Online Growth Momentum

Hospital pharmacies held 46.43% revenue in 2024, reflecting acute-care protocols during manic crises and the controlled handling requirements of LAIs. Integrated medication-therapy management supports dosing titrations and side-effect monitoring, crucial during stabilization.

Online pharmacies, projected to expand at 5.45% CAGR, meet rising demand for home delivery and telepharmacy counseling. Digital workflows streamline prior authorization for costly LAIs and prescription apps, reducing start-of-therapy delays. Omnichannel models that blend in-person oversight with digital convenience broaden patient engagement and enlarge the bipolar disorders treatment market size globally.

Bipolar Disorders Treatment Market: Market Share by Distribution Channel
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By Treatment Setting: Inpatient Care Leads While Digital Therapeutics Transform Home-Based Treatment

Inpatient settings accounted for 53.45% of spending in 2024 as hospitalization remains the gold standard for acute mania management and suicidality. Average stays of 7-14 days permit rapid medication titration and safety monitoring, justifying hospital pharmacy dominance.

Digital therapeutics grow fastest at 5.76% CAGR through 2030, complementing outpatient follow-up with CBT modules and wearable-enabled monitoring. FDA-cleared apps, remote vital-sign tracking, and telepsychiatry visits reduce emergency-room use and enhance adherence. Hybrid care models that integrate inpatient stabilization with tech-enabled home support enlarge the bipolar disorders treatment market while lowering per-patient costs.

Geography Analysis

North America dominated the bipolar disorders treatment market with 42.56% share in 2024. Parity-law enforcement effective 2025 obliges health plans to match mental-health benefits with medical coverage. Early uptake of LAIs and rapid pathways for digital therapeutics speed diffusion of innovation. FDA approvals for Uzedy and Fanapt reinforce treatment diversity, while integrated delivery networks negotiate value-based contracts that reward relapse reduction.

Europe maintains robust demand through centralized EMA approvals that streamline cross-border launches. Universal healthcare financing guarantees baseline access, although country-specific health-technology assessments steer price negotiations. Variability in legacy lithium use reflects differing monitoring infrastructures, and post-Brexit divergence may lengthen UK-specific timelines for certain agents.

Asia-Pacific is the fastest-growing region at 3.56% CAGR. China’s regulatory reforms trimmed NDA review times and widened reimbursement for innovative therapies, strengthening commercial cases for novel agents. Japan’s annual drug-price revisions nudge manufacturers to pursue high-value indications, while India’s generic manufacturing base rises as a global supplier. Nonetheless, limited specialist density and diagnostic under-recognition still temper treated-prevalence gains, leaving substantial headroom in the bipolar disorders treatment market.

Bipolar Disorders Treatment Market CAGR (%), Growth Rate by Region
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Competitive Landscape

Johnson & Johnson’s USD 14.6 billion purchase of Intra-Cellular Therapies positions Caplyta for an estimated USD 5 billion peak in annual sales and signals renewed pursuit of neuropsychiatric leadership. AbbVie, now marketing Vraylar, leverages Gilgamesh collaboration to access neuroplastogen assets, committing USD 65 million upfront with milestones worth USD 1.95 billion. Otsuka builds on Abilify’s franchise by pairing prescription drugs with proprietary digital therapeutics, extending engagement beyond pill adherence.

Patent cliffs reshape revenue streams: aripiprazole generics arrive in January 2025, prompting price erosions of up to 70%, while Vraylar remains protected until 2029. Lifecycle management focuses on LAI reformulations and expanded mood-disorder indications. Digital-health convergence creates new battlegrounds; companies integrate AI-powered adherence platforms to differentiate beyond molecule efficacy.

Moderate consolidation defines the field. Top five brands account for about two-thirds of branded revenue, yet over 100 generics supply lithium, valproate, and legacy SGAs. Strategic M&A, pipeline diversification, and payer-linked digital tools are emerging as prime levers to secure durable advantage across the bipolar disorders treatment market.

Bipolar Disorders Treatment Industry Leaders

  1. Johnson & Johnson (Janssen)

  2. Otsuka Holdings Co. Ltd.

  3. AbbVie Inc.

  4. Eli Lilly and Company

  5. AstraZeneca plc

  6. *Disclaimer: Major Players sorted in no particular order
Bipolar Disorders Treatment Market
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Need More Details on Market Players and Competitors?
Download PDF

Recent Industry Developments

  • February 2025: Johnson & Johnson closed its USD 14.6 billion purchase of Intra-Cellular Therapies, adding Caplyta for bipolar I and II depression and projecting peak annual sales above USD 5 billion.
  • February 2025: FDA accepted Teva and Medincell’s sNDA for Uzedy extended-release risperidone for bipolar I maintenance based on RISE and SHINE trials.
  • January 2025: Autobahn Therapeutics began a phase-2 trial of ABX-002 as adjunctive therapy for bipolar depression after securing USD 100 million in series-C funding.
  • October 2024: AbbVie and Gedeon Richter broadened their partnership to include ABBV-932 for bipolar depression.
  • September 2024: U.S. Departments of Labor, Treasury, and Health finalized Mental-Health Parity Act rules extending equivalent coverage to more than 175 million insured Americans.

Table of Contents for Bipolar Disorders Treatment Industry Report

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Bipolar Disorder
    • 4.2.2 Rising initiative by Government Institutes to Increase the Awareness
    • 4.2.3 Technological Advancements
  • 4.3 Market Restraints
    • 4.3.1 Side Effects Associated with Bipolar Drugs
    • 4.3.2 Misdiagnosis of Bipolar Disorder
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION

  • 5.1 By Drug Class
    • 5.1.1 Mood stabilizer
    • 5.1.2 Anticonvulsant
    • 5.1.3 Antipsychotic Drug
    • 5.1.4 Antidepressant Drug
    • 5.1.5 Other Classes of Drug
  • 5.2 By Mechanism of Action
    • 5.2.1 Selective Serotonin Reuptake Inhibitor
    • 5.2.2 Serotonin Norepinephrine Reuptake Inhibitor
    • 5.2.3 Tricyclic Antidepressant Drug
    • 5.2.4 Beta Blockers
    • 5.2.5 Others
  • 5.3 Geography
    • 5.3.1 North America
    • 5.3.1.1 United States
    • 5.3.1.2 Canada
    • 5.3.1.3 Mexico
    • 5.3.2 Europe
    • 5.3.2.1 Germany
    • 5.3.2.2 United Kingdom
    • 5.3.2.3 France
    • 5.3.2.4 Italy
    • 5.3.2.5 Spain
    • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia - Pacific
    • 5.3.3.1 China
    • 5.3.3.2 Japan
    • 5.3.3.3 India
    • 5.3.3.4 Australia
    • 5.3.3.5 South Korea
    • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
    • 5.3.4.1 GCC
    • 5.3.4.2 South Africa
    • 5.3.4.3 Rest of Middle-East and Africa
    • 5.3.5 South America
    • 5.3.5.1 Brazil
    • 5.3.5.2 Argentina
    • 5.3.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 AbbVie Inc.
    • 6.1.2 Allergan PLC
    • 6.1.3 AstraZeneca Plc
    • 6.1.4 Eli Lilly and Company
    • 6.1.5 GlaxoSmithKline Plc
    • 6.1.6 Janssen Pharmaceuticals Inc.
    • 6.1.7 Novartis AG
    • 6.1.8 Otsuka Holdings Co. Ltd
    • 6.1.9 Pfizer Inc.
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Global Bipolar Disorders Treatment Market Report Scope

As per the scope of this report, bipolar disorder is a mental illness marked by extreme shifts in mood. Symptoms may include an extremely elevated mood called mania, and also episodes of depression. Bipolar disorder is also known as bipolar disease or manic depression. People with bipolar disorder may have trouble managing everyday life tasks at school or work, or maintaining relationships. There's no cure, but there are many treatment options available that can help with managing the symptoms. The Bipolar Disorder Market is segmented by Drug Class (Mood stabilizer, Anticonvulsant, Antipsychotic Drug, Antidepressant Drug, and Other Classes of Drug), by Mechanism of Action (Selective Serotonin Reuptake Inhibitor, Serotonin Norepinephrine Reuptake Inhibitor, Tricyclic Antidepressant Drug, Beta Blockers, Others), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.

By Drug Class Mood stabilizer
Anticonvulsant
Antipsychotic Drug
Antidepressant Drug
Other Classes of Drug
By Mechanism of Action Selective Serotonin Reuptake Inhibitor
Serotonin Norepinephrine Reuptake Inhibitor
Tricyclic Antidepressant Drug
Beta Blockers
Others
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia - Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa GCC
South Africa
Rest of Middle-East and Africa
South America Brazil
Argentina
Rest of South America
By Drug Class
Mood stabilizer
Anticonvulsant
Antipsychotic Drug
Antidepressant Drug
Other Classes of Drug
By Mechanism of Action
Selective Serotonin Reuptake Inhibitor
Serotonin Norepinephrine Reuptake Inhibitor
Tricyclic Antidepressant Drug
Beta Blockers
Others
Geography
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia - Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa GCC
South Africa
Rest of Middle-East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

What is the current size of the bipolar disorder market?

The bipolar disorder market stands at USD 5.01 billion in 2025 and is projected to reach USD 5.82 billion by 2030.

Which drug class leads revenue?

Second-generation antipsychotics generate the largest revenue, holding 51.45% market share in 2024.

Which segment is growing fastest?

Digital therapeutics within home-based care display the fastest CAGR at 5.76% through 2030.

Why is North America the largest regional market?

Strong insurance coverage under parity laws, rapid approval pathways, and early adoption of LAIs drive North America’s 42.56% share.

What safety concerns limit SGA use?

Weight gain and metabolic syndrome affect up to 13% of patients, prompting intensive monitoring and exploration of GLP-1 adjuncts.

How will patent expirations affect competition?

Aripiprazole’s January 2025 patent expiry will intensify generic competition and cut branded prices by as much as 70%, reshaping revenue distribution.

Page last updated on: June 26, 2025

Bipolar Disorders Treatment Market Report Snapshots

Compare market size and growth of Bipolar Disorders Treatment Market with other markets in Healthcare Industry